Ladenburg Thalmann Financial Services’s Oramed Pharmaceuticals ORMP Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$3K	Hold	500	–	–	﹤0.01%	4975
2019 Q3	$2K	Hold	500	–	–	﹤0.01%	4982
2019 Q2	$2K	Hold	500	–	–	﹤0.01%	4988
2019 Q1	$2K	Hold	500	–	–	﹤0.01%	4957
2018 Q4	$2K	Hold	500	–	–	﹤0.01%	4911
2018 Q3	$2K	Hold	500	–	–	﹤0.01%	4901
2018 Q2	$3K	Hold	500	–	–	﹤0.01%	4770
2018 Q1	$3K	Buy	+500	New	+$3.86K	﹤0.01%	4770
2017 Q3	–	Sell	-500	Closed	-$4K	–	4991
2017 Q2	$4K	Hold	500	–	–	﹤0.01%	4396
2017 Q1	$3K	Sell	500 -1,500	-75%	-$9.33K	﹤0.01%	4474
2016 Q4	$12K	Hold	2,000	–	–	﹤0.01%	3780
2016 Q3	$15K	Hold	2,000	–	–	﹤0.01%	3574
2016 Q2	$17K	Hold	2,000	–	–	﹤0.01%	3447
2016 Q1	$13K	Hold	2,000	–	–	﹤0.01%	3545
2015 Q4	$17K	Buy	2,000 +1,000	+100%	+$7.58K	﹤0.01%	3343
2015 Q3	$5K	Hold	1,000	–	–	﹤0.01%	3944
2015 Q2	$6K	Hold	1,000	–	–	﹤0.01%	3976
2015 Q1	$6K	Buy	+1,000	New	+$4.83K	﹤0.01%	3900
2014 Q4	–	Sell	-369	Closed	-$3K	–	4406
2014 Q3	$3K	Buy	+369	New	+$3.28K	﹤0.01%	3579

Other funds holding ORMP

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

JSMC

Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RPC

Rossmore Private Capital Glastonbury, Connecticut $1.14B AUM 23.53% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ladenburg Thalmann Financial Services's ORMP Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services held its Oramed Pharmaceuticals (ORMP) position steady in Q4 2019 at 500 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #4975.

Ladenburg Thalmann Financial Services first reported a position in ORMP in Q3 2014 and has held it in 19 quarters since. The position peaked at $17K in Q2 2016. 30 funds tracked by Wall St. Rank hold ORMP as of Q4 2019.

Ladenburg Thalmann Financial Services held 500 shares of Oramed Pharmaceuticals worth $3K as of Q4 2019.
Ladenburg Thalmann Financial Services left its Oramed Pharmaceuticals share count unchanged in Q4 2019.
Oramed Pharmaceuticals made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #4975 holding.
Ladenburg Thalmann Financial Services first reported a position in Oramed Pharmaceuticals in Q3 2014 and has held it in 19 quarters since.
Ladenburg Thalmann Financial Services's Oramed Pharmaceuticals position peaked at $17K in Q2 2016.
30 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.